Enanta Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference Presentation to be Webcast on January ...
January 04 2016 - 8:00AM
Business Wire
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and
development-focused biotechnology company dedicated to creating
small molecule drugs for viral infections and liver diseases, today
announced that Jay R. Luly, Ph.D., President and Chief Executive
Officer, will make a formal company presentation on January 13,
2016, at 11:00 a.m. PT at the 34th Annual J.P. Morgan Healthcare
Conference in San Francisco. The presentation will contain a
business overview and an update on Enanta’s research and
development pipeline. A question and answer session with investors
will follow the presentation.
A live webcast and replay of the presentation, as well as the
question and answer breakout session that follows the presentation
will be accessible by visiting the “Calendar of Events” section on
the “Investors” page of Enanta’s website at www.enanta.com. The
replay webcast will be available following the presentation and
will be archived for approximately 60 days.
About EnantaEnanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases.
Enanta has developed novel protease and NS5A inhibitors that are
members of the direct-acting-antiviral (DAA) inhibitor classes
designed for use against the hepatitis C virus (HCV). Enanta’s
protease inhibitors partnered with AbbVie include paritaprevir,
which is contained in AbbVie’s marketed DAA regimens for HCV, and
ABT-493, Enanta’s next-generation protease inhibitor which AbbVie
is developing in phase 3 studies in combination with ABT-530,
AbbVie’s next-generation NS5A inhibitor. Enanta also has discovered
EDP-494, a host-targeted antiviral (HTA) inhibitor for HCV targeted
against cyclophilin, which Enanta plans to study in a phase 1
clinical trial beginning in the first quarter of calendar 2016. In
addition, Enanta plans to advance into clinical development later
in 2016 its program in non-alcoholic steatohepatitis, or NASH, a
condition that results in liver inflammation and liver damage
caused by a buildup of fat in the liver.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160104005180/en/
Investor ContactEnanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jul 2023 to Jul 2024